Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448536 · ClinicalTrials.gov registry record · Phase 4
A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 201
- Enrollment target
NCT03448536 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 201 participants.
The verdict
NCT03448536, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the maximum single dose of Aleve® (two tablets, equivalent to 440 mg of naproxen sodium) to the maximum single dose of Tylenol Extra Strength (two caplets, equivalent to 1000 mg of acetaminophen) in the treatment of menstrual pain associated with primary dysmenorrhea.
Interventions
- DRUG Naproxen Sodium, (Aleve, BAY117031)
- DRUG Acetaminophen (Tylenol Extra Strength)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2018-04-05 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03448536
The ClinicalTrials.gov registry entry for NCT03448536 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen Sodium, (Aleve, BAY117031) is the first listed.
NCT03448536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03448536 about?
NCT03448536 is a clinical study titled "A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea". The purpose of this study is to compare the maximum single dose of Aleve® (two tablets, equivalent to 440 mg of naproxen sodium) to the maximum single dose of Tylenol Extra Strength (two caplets, equivalent to 1000 mg of acetaminophen) in the treatment of menstrual pain associated with primary dysme...
What is the current status of trial NCT03448536?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 201 participants. The study started on 2018-04-05. Estimated completion is 2018-09-05.
What interventions are being tested in trial NCT03448536?
The interventions under investigation include: Naproxen Sodium, (Aleve, BAY117031) (DRUG), Acetaminophen (Tylenol Extra Strength) (DRUG).
Who is sponsoring clinical trial NCT03448536?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.